BRD7 and prostate carcinoma: Down-regulation of BRD7 expression has been observed in several malignancies and is correlated with poor prognosis of various cancer types, including breast (32), colorectal (33), gastric (29), and prostate cancer (34), as well as hepatocellular carcinoma (35), and osteosarcoma (36).